RLMD Stock Summary and Trading Ideas (Relmada Therapeutics | NASDAQ:RLMD)

Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

Relmada Therapeutics trades on the NASDAQ stock market under the symbol RLMD.

As of December 24, 2025, RLMD stock price climbed to $4.60 with 327,148 million shares trading.

RLMD has a beta of 1.19, meaning it tends to be more sensitive to market movements. RLMD has a correlation of 0.02 to the broad based SPY ETF.

RLMD has a market cap of $337.33 million. This is considered a Small Cap stock.

In the last 3 years, RLMD traded as high as $7.22 and as low as $.24.

The top ETF exchange traded funds that RLMD belongs to (by Net Assets): PSIL, VXF.

RLMD has outperformed the market in the last year with a price return of +1111.8% while the SPY ETF gained +17.3%. RLMD has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +175.4% and +11.1%, respectively, while the SPY returned +4.4% and +1.4%, respectively.

RLMD support price is $4.17 and resistance is $4.81 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RLMD shares will trade within this expected range on the day.